Johnson & Johnson launches COVID vaccine candidate trial

Janssen Pharmaceuticals distributed the following information… 

Since January 2020, Johnson & Johnson and its Janssen Pharmaceutical Companies have been committed to combatting the COVID-19 pandemic through the development of a COVID-19 vaccine candidate.

Johnson & Johnson has launched its Phase 3 ENSEMBLE trial to determine the efficacy (whether it works) and safety of Janssen’s investigational vaccine for the prevention of COVID-19. The ENSEMBLE trial aims to recruit up to 60,000 participants and is being conducted with the highest scientific and ethical standards. It is essential to include all types of people in clinical trials when researching and developing new vaccines, to help ensure they are safe and effective for those disproportionately impacted.

Research has shown that certain diseases and medications may impact people differently based on their age, gender, and genetic background, including race and/or ethnicity. For example, COVID-19 has disproportionally impacted both older people and minority populations. The ENSEMBLE trial aims to ensure diverse representation of communities who have been disproportionately affected by the pandemic. In the U.S., this includes significant representation of Black, Hispanic/Latinx, American Indian and Alaskan Native participants.

For more information on the importance of diversity in clinical research, visit, an educational resource that addresses questions regarding gender, race, ethnicity, age, and lifestyle for participants who are looking to get involved in clinical trials.

To learn more about Johnson & Johnson’s ENSEMBLE trial and determine if you are eligible to participate in the study, visit